Triglyceride-glucose index as a potential evaluation tool for all-cause mortality in ischemic stroke patients undergoing endovascular therapy: a multicenter cohort study

甘油三酯-葡萄糖指数作为缺血性卒中患者血管内治疗全因死亡率的潜在评估工具:一项多中心队列研究

阅读:2

Abstract

BACKGROUND: The triglyceride-glucose (TyG) index has demonstrated a significant association with stroke outcomes. However, its prognostic value in acute ischemic stroke (AIS) patients undergoing endovascular therapy (EVT) remains inadequately explored. This study aims to evaluate the association between the TyG index and all-cause mortality in AIS patients undergoing EVT. METHODS: This was a multicenter, retrospective cohort study that included AIS patients undergoing EVT between September 2018 and January 2024. Kaplan-Meier survival analysis was performed to evaluate survival differences across TyG tertiles for both in-hospital and 90-day. Cox proportional hazards regression and restricted cubic splines (RCS) were used to examine the association between the TyG index and all-cause mortality. Additionally, interaction and subgroup analyses were conducted to evaluate the robustness and consistency of the results. RESULTS: Among EVT patients (median age 69 years, 56.0% male), the in-hospital and 90-day mortality rates were 7.9% and 19.1%, respectively. Cox regression analysis revealed that an elevated TyG index was significantly associated with both in-hospital mortality (adjusted hazard ratio [HR] = 1.79; 95% CI = 1.27–2.53; P < 0.001) and 90-day mortality (HR = 1.44; 95% CI = 1.16–1.79; P < 0.001). RCS analysis demonstrated a positive linear relationship between the TyG index and all-cause mortality. Importantly, subgroup analysis revealed that diabetes modified the relationship between the TyG index and mortality, with a stronger effect in the non-diabetic subgroup (P for interaction = 0.011 and 0.022, respectively). CONCLUSION: The TyG index is significantly associated with all-cause mortality in non-diabetic AIS patients undergoing EVT, suggesting that it may serve as a potential evaluation tool for risk stratification in this patient population. CLINICAL TRIAL NUMBER: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-026-02206-0.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。